Repositioning Candidate Details
| Candidate ID: | R0484 |
| Source ID: | DB01303 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Oxtriphylline |
| Synonyms: | Choline theophyllinate; Choline theophylline; Oxtriphylline; Theocolin |
| Molecular Formula: | C12H21N5O3 |
| SMILES: | C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O |
| Structure: |
|
| DrugBank Description: | Oxtriphylline is the choline salt form of . Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines). It is marketed under the name Choledyl SA, and several forms of oxytriphylline have been discontinued. In the US, oxtriphylline is no longer available. |
| CAS Number: | 4499-40-5 |
| Molecular Weight: | 283.3268 |
| DrugBank Indication: | Used to treat the symptoms of asthma, bronchitis, COPD, and emphysema. |
| DrugBank Pharmacology: | Oxtriphylline is a bronchodilator. Oxtriphylline works in several ways: it relaxes muscles in your lungs and chest to allow more air in, decreases the sensitivity of your lungs to allergens and other substances that cause inflammation, and increases the contractions of your diaphragm to draw more air into the lungs. |
| DrugBank MoA: | Oxtriphylline is a choline salt of theophylline. After ingestion, theophylline is released from oxytriphylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin. |
| Targets: | cGMP-inhibited 3',5'-cyclic phosphodiesterase A inhibitor; cAMP-specific 3',5'-cyclic phosphodiesterase 4A inhibitor; Adenosine receptor A2a antagonist; Adenosine receptor A1 antagonist; Histone deacetylase 2 activator |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|